Resources
63 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/26/2024
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about nitazenes.
Posted 1/23/2024 (updated 3/28/2024)
As RCORP Grantees continue to build and grow partnerships with Indigenous peoples and communities, further information is needed to support these partnerships through building trust, understanding community dynamics, and recognizing the importance of patient-centered care.
Posted 12/12/2023 (updated 3/28/2024)
Given the epidemic of increased maternal mortality and morbidity in the U.S., there is growing sentiment on how to mitigate preventable causes, including that of addressing substance use disorder (SUD). This webinar provided information on the complications of SUD in pregnancy, along with methods for effective intervention and management for clinicians and collaborators.
Posted 11/17/2023 (updated 3/28/2024)
Celebrate and honor the culture, traditions, and achievements of the nation's original inhabitants and of their descendants. The U.S Department of Health and Human Services (HHS) and the HHS Office of Minority Health (OMH) honor the history, culture, and legacy of Tribal nations and Indigenous communities across the United States.
Posted 11/6/2023 (updated 3/28/2024)
The John Hopkins Center for Indigenous Health launched the new Tribal Principles website which offers culturally relevant, Indigenous-centered guidance for Tribes to consider when creating spending plans for the use of Tribal opioid settlements. This work complements the broad state/national settlement guidance led at the Johns Hopkins Bloomberg School of Public Health.
Posted 10/23/2023 (updated 5/24/2024)
Using data from 77 harm reduction programs in 25 US states, researchers found that 12-15% of powder methamphetamine and powder cocaine also contained fentanyl although the prevalence varied geographically. Prevalence of fentanyl in crystal methamphetamine and crack cocaine was lower. Heroin and xylazine were also found in unregulated stimulants. Xylazine reduced the ability to detect fentanyl.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/31/2023 (updated 3/26/2024)
This presentation will cover health equity regarding rural American Indian and Alaska Native (AI/AN) communities' prevention and treatment efforts to address substance use disorder (SUD), including the need for contingency management for stimulants.